Drug
MK-0752 clinical trials
Also written MK-0752.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 4 |
| 2010 | 2 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 1
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 4
Merck Sharp & Dohme LLC (4) · Loyola University (1) · Cancer Research UK (1) · University of Michigan Rogel Cancer Center (1) · Pediatric Brain Tumor Consortium (1)
Often tested with
Tested in the same studies.
MK 2206 (2) · Gemcitabine (1) · Docetaxel (1) · Pegfilgrastim (1) · Ridaforolimus (1)
Studies
Open first, then newest update. How each study uses MK-0752 is read from its arms, and is right about nine times in ten.
Testing it · 8
- Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast CancerCompletedPhase 4Loyola UniversityNCT00756717Written as MK-0752
- A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01243762Written as MK-0752
- A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase InhibitorCompletedPhase 1Merck Sharp & Dohme LLCNCT00803894Written as MK0752
- MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedPhase 1Cancer Research UKNCT01098344Written as Notch signaling pathway inhibitor MK0752
- Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)CompletedPhase 1Merck Sharp & Dohme LLCNCT01295632Written as MK-0752
- A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)TerminatedPhase 1Merck Sharp & Dohme LLCNCT00100152Written as MK0752, (Notch Inhibitor)
- Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast CancerCompletedPhase 1/2University of Michigan Rogel Cancer CenterNCT00645333Written as MK-0752, Docetaxel, Pegfilgrastim
- MK0752 in Treating Young Patients With Recurrent or Refractory CNS CancerTerminatedPhase 1Pediatric Brain Tumor ConsortiumNCT00572182Written as MK-0752
Codes
What other systems call MK-0752 · ClinicalTrials.gg INT005748
- UNII (FDA) 9JD9B4S53TMK-0752Confirmed FDA, Wikidata
- Wikidata Q27272627MK-0752Confirmed FDA, Wikidata
- DrugBank DB12852One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9JD9B4S53T | MK-0752 | Confirmed FDA, Wikidata |
| Wikidata | Q27272627 | MK-0752 | Confirmed FDA, Wikidata |
| DrugBank | DB12852 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.